Workflow OS for pain clinics to win reimbursement, manage 60-day temporary PNS therapy, and prove outcomes before implants.

1. A $650M strategic acquisition means temporary PNS is now important enough for a top neuromodulation incumbent to buy outright, which gives clinics confidence that the category is here to stay.
2. Clinics can now point to 50,000 implants and 71% significant pain relief in real-world patients, making program rollout easier to justify internally and to referral partners.
3. Category growth is being driven by expanding reimbursement and stronger clinical evidence, so the constraint shifts from device validity to operational execution inside the clinic.
4. Temporary PNS creates a new earlier-intervention step between conservative care and permanent implants, which opens a distinct workflow that most clinics were not built to run.
5. Incumbents are building pain portfolios and selling hardware, leaving room for an independent workflow layer that helps clinics run multi-vendor temporary PNS programs and benchmark outcomes.

Catalyst. Medtronic's purchase of SPR, paired with explicit signals around reimbursement expansion and earlier-intervention demand, shows clinics now have both strategic cover and market pressure to operationalize temporary PNS quickly.

The product gives a pain clinic a dedicated operating layer for temporary PNS instead of forcing the therapy through generic procedure scheduling and note templates. It identifies likely candidates from referral and visit data, assembles the documentation package needed to show failed conservative care, and tracks benefits and authorization status before a lead is placed. Once therapy begins, it runs the 60-day episode with patient check-ins, symptom tracking, escalation rules, and milestone reminders for staff. At the end of the episode, it produces physician-friendly summaries plus payer- and referrer-ready outcomes reports that help the clinic decide who should graduate to additional interventions and which referral sources are sending the best-fit patients.

What's different. This is not another neuromodulation device company and not a generic remote-monitoring app. The defensible wedge is owning the operational system of record for temporary PNS episodes across authorization, care coordination, patient follow-up, and post-therapy outcomes. If the company becomes the easiest way for independent pain clinics to launch and benchmark temporary PNS, it can build the multi-clinic outcomes dataset and workflow lock-in that device manufacturers and generic EHRs lack.

Jobs to be done

flowchart LR
  Buyer[Pain clinic operator] --> Pain[Manual temporary PNS program workflow]
  Pain --> Product[Temporary PNS clinic OS]
  Product --> Outcome[Faster launches and provable outcomes before implants]

Executive takeaways

• Temporary PNS is now strategically validated, but clinic execution remains the bottleneck rather than therapy legitimacy.
• The best wedge is a vendor-neutral operating layer for authorizations, 60-day follow-up, and outcomes proof before permanent implants.
• Incumbent competition is real but still device-centric; that leaves room for software that helps independent pain groups run multi-vendor programs.
• The near-term market is not huge, but it is focused, fragmented, and operationally painful enough to support a high-ACV workflow product.

Market definition

Workflow software for independent U.S. interventional pain groups that launch and manage temporary peripheral nerve stimulation episodes, from candidate triage and authorization through 60-day follow-up and outcomes reporting. The category excludes device manufacturing, generic EHR modules, and permanent neuromodulation hardware itself.

Customer and buyer

Initial users are nurse coordinators, prior-authorization staff, and operations managers inside independent or PE-backed interventional pain groups. The economic buyer is typically the medical director, practice COO, or group administrator who owns procedure growth, staffing efficiency, and payer-facing documentation risk.

Buying triggers

• Strategic validation from Medtronic's SPR deal and CMS payment support makes temporary PNS feel like a category clinics should operationalize now rather than watch from the sidelines. [1][5]
• Prior authorization, benefits verification, and appeal work are already consuming meaningful staff time across physician practices, which makes a narrower, pain-program workflow problem easier to budget against. [3][13][14][15]
• Clinics need a disciplined step-up workflow because permanent neuromodulation pathways still require documented trial success, functional improvement, and clean records. [16][17][34]

Willingness to pay

There is believable budget because temporary PNS already triggers manual authorization, payer communication, and follow-up work that clinics either absorb with staff time or push to manufacturer support. A product that shortens approval time, reduces drop-off, and produces payer-ready outcomes documentation can sell as labor avoidance plus procedure-growth enablement rather than as a speculative digital add-on. [3][13][14][15]

Category dynamics

Growth signal 25%+ 2026 revenue growth guidance for Nalu as a category proxy, not a pure market CAGR

Validation signals

• Medtronic's $650M purchase of SPR is hard evidence that temporary PNS is strategically important to a top neuromodulation incumbent.
• CMS explicitly lists SPRINT under the non-opioid treatments payment framework with HCPCS C9807.
• The buyer base is real and fragmented, with more than 900 active pain management physician group practices in the U.S.
• Published evidence now supports both durable benefit in shoulder pain and cost-savings logic for 60-day-first PNS pathways.

Regulatory & technical constraints

• Qualified temporary separate payment support is specific to CMS outpatient settings and a defined policy window, so commercialization cannot assume universal payer parity.
• Medicare still distinguishes diagnostic trial use and implanted-device coverage under separate nerve-stimulator determinations.
• Permanent neuromodulation escalation requires documented successful trial results, functional improvement, and strong record quality.
• Clinical success is sensitive to patient-selection quality, especially where psychological distress or opioid dependence are present.

The competitive field is crowded with device vendors, not workflow-native software. SPR/Medtronic owns the temporary category narrative, Boston Scientific/Nalu and Bioventus address broader or permanent PNS use cases, and Mainstay/Curonix validate adjacent neuromodulation spend. The default substitute inside the clinic is still a messy mix of EHR templates, rep coordination, prior-auth specialists, and manual check-ins.

Why incumbents do not win by default

• Device OEMs. OEMs are strong at therapy education and reimbursement support, but they optimize for selling their own device rather than acting as a neutral operating system across referral, authorization, and multi-vendor outcomes benchmarking.
• Generic EHR and RCM tools. Generic records and revenue-cycle systems can store data, but they do not solve pain-program-specific triage, episode milestone management, or payer-packet assembly by default.
• Permanent neuromodulation incumbents. The implant pathway is well developed, but its documentation and trial logic are built around permanent stimulation rather than a reversible 60-day episode that needs frequent staff touchpoints and proof before escalation.
• Large pain MSOs. Consolidators bring scale and purchasing leverage, but fragmentation and PE roll-up activity imply many groups still need standardization tools rather than already having best-in-class workflow infrastructure.

This company should be built as a temporary peripheral nerve stimulation operating system for independent U.S. interventional pain groups that want to add a non-opioid step before permanent implants without adding a full new program team. The first customer is a 5-10 site pain group with existing spinal cord stimulation capability where a medical director or COO has decided to launch temporary PNS after reimbursement confidence, OEM outreach, or competitive pressure makes delay costly. The immediate pain is not whether the therapy works; it is the manual episode work across candidate triage, benefits verification, prior authorization, scheduling, 60-day follow-up, and outcomes reporting. The initial product should stay narrow to that workflow: candidate selection, payer packet assembly, coordinator worklists, patient check-ins, and end-of-episode documentation for temporary PNS only. This beachhead is faster to prove than a broader pain-clinic OS because time to first case, completed episodes, and documented outcomes can all move inside a single 60-day cycle. Go-to-market and pricing should stay coupled to the same motion: a paid pilot for one group, then an annual contract plus per-episode fees once the clinic sees faster approvals, less patient drop-off, and cleaner evidence for payers and referrers. The strongest long-term advantage is a vendor-neutral dataset of payer workflows, patient-selection patterns, and episode outcomes that OEMs and generic EHR modules do not naturally own. The main gaps are direct evidence on current clinic leakage and staff time, plus how durable reimbursement tailwinds remain after the current CMS policy window, so the first 18 months should buy proof on those points rather than broad product expansion.

Problem

• Independent pain clinics that want to add temporary PNS still run candidate identification, conservative-care documentation, benefits checks, prior authorization, scheduling, and 60-day follow-up across EHR templates, device reps, and nurse phone calls.
• That fragmentation delays launch, causes patient leakage between consult and lead placement, and leaves clinics without auditable outcomes documentation when deciding whether to escalate care or justify reimbursement.

Solution

• Provide a vendor-neutral workflow layer for temporary PNS that centralizes candidate triage, payer-packet assembly, authorization status, procedure scheduling, and staff task management.
• Run the 60-day episode with patient check-ins, milestone reminders, symptom capture, and escalation rules so clinics complete more episodes with usable documentation.
• Generate physician-, payer-, and referrer-ready end-of-episode summaries that support next-step decisions and create reusable outcomes benchmarks across clinics.

Why we win

• The product is specialized around temporary PNS episode operations rather than generic pain-clinic software or a single OEM's reimbursement program.
• The buying trigger is concrete because budget appears when a clinic decides to launch temporary PNS and needs time-to-first-case proof quickly.
• Vendor neutrality matters because clinics do not want their operating layer tied to one manufacturer if they need multi-vendor leverage or benchmarking credibility.
• If the company captures denial patterns, staffing workflows, and outcomes by indication across fragmented pain groups, it can build a defensible workflow and benchmarking moat.

Milestones

flowchart LR
  Wedge[Temporary PNS clinic wedge] --> MVP[Episode workflow MVP]
  MVP --> Proof[Faster first cases and cleaner outcomes]
  Proof --> Expansion[Multi-clinic pain pathway data layer]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least 3 of the first 10 serious target groups will pay for a pilot instead of asking the startup to work through OEM support or free implementation help.
• The first 5 live deployments improve authorization cycle time or consult-to-procedure conversion by at least 20% versus baseline.
• At least 80% of active episodes on the platform finish with usable outcomes documentation that the clinic will show to payers or referrers.
• At least 2 early customers convert from paid pilot to annual production contracts at ACVs consistent with the modeled market.
• At least 30% of early customers expand to additional sites or adjacent neuromodulation workflows within 12 months of first go-live.

Open diligence questions

• How much staff time and patient leakage exist today between consult, authorization, lead placement, and final outcomes reporting?
• Will clinics buy this as a standalone workflow product or insist it be bundled through OEM or RCM partners?
• Which payer mixes and geographies should the company target first to avoid reimbursement-edge cases dominating the roadmap?
• Can v1 prove ROI without deep EHR write-back, or will integration scope delay deployment and compress margins?
• How quickly will OEMs respond with bundled lightweight workflow tooling if this wedge starts working?

Model sanity

• Revenue engine. Base-case revenue comes from turning 3 Y1 paid pilots into 10 customer groups by Q4Y2 and 18 by Q4Y3 at a blended $150K-$160K annual customer value.
• Must go right. At least 2 early pilots need to convert into annual contracts and create one multi-site rollout proof point, or the modeled CAC payback and referral motion will not hold.
• Model breaks if. A one-quarter sales-cycle slip plus lower reimbursement confidence pushes the downside case toward $1.71M of Y3 revenue and sends cash below zero before the next round.
• Next-round proof. The next financing case is strongest once the company reaches 8-10 groups by Q4Y2, proves one durable channel, and shows a credible path to the 18-group SOM with benchmark upsell.

Scenarios

Sensitivity

flowchart LR
  QualifiedGroups[Qualified pain groups] --> PaidPilots[Paid pilots]
  PaidPilots --> ProductionGroups[Production customer groups]
  ProductionGroups --> ManagedEpisodes[Managed temporary PNS episodes]
  ManagedEpisodes --> Revenue[Subscription and episode revenue]
  Revenue --> GrossProfit[Gross profit after implementation and support COGS]
  GrossProfit --> Cash[Cash runway]

Flags: The model assumes clinics will still budget standalone workflow software instead of defaulting to OEM reimbursement support, which the BP explicitly says still needs live proof. · Gross margin only reaches the 72% target in H2Y3; if integrations or reimbursement ops stay bespoke, the seed round would need to be larger. · Revenue remains concentrated in a small number of customer groups, so one delayed multi-site rollout can move a quarter by roughly $40K-$80K and pressure the cash buffer.

• Reimbursement fragmentation. Coverage, coding confidence, and documentation standards for temporary PNS can vary by payer and geography, which can slow clinic adoption. Mitigation: Start with clinics and payer mixes where reimbursement is already established, then codify winning authorization packets and coverage playbooks into the product.
• Incumbent channel squeeze. Medtronic, Boston Scientific, or their field teams could bundle lightweight workflow support to protect the device relationship. Mitigation: Stay vendor-neutral, prove better conversion and outcomes across multiple device options, and make the product the independent clinic's control layer rather than a single-manufacturer add-on.
• Weak patient selection. If clinics enroll poor-fit patients, outcomes will look noisy and the software may be blamed for a therapy-design problem. Mitigation: Build strict candidate-triage workflows, benchmark outcomes by indication and referral source, and focus initial customers that already have disciplined interventional pain programs.